http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-055618-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| filingDate | 2006-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2007-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-055618-A1 |
| titleOfInvention | DIAMINOPIRIMIDINAS AS MODULATORS OF P2X3 AND P2X2 / 3, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF RELATED DISEASES. |
| abstract | Medications are also provided that use the compounds to treat diseases mediated by P2X3 p P2X2 / 3 receptor antagonists and pharmaceutical compositions comprising them. Claim 1: A compound of the formula (1) or a pharmaceutically acceptable salt thereof, wherein X is -CH2-; -Or are-; or -NRc-; wherein n ranges from 0 to 2 and Rc is H or alkyl; D is an optional O; one or two of A, E, G, J, Y and Z are N while the others are CRa; or A, E, G, J, Y and Z are CRa; R1 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, halo, haloalkyl, or hydroxyalkyl; each Ra is independently H, alkyl, alkenyl, amino, aminosulfonyl, halo, amido, haloalkyl, alkoxy, hydroxy, haloalkoxy, nitro, amino, hydroxyalkyl, alkoxyalkyl, hydroxyalkoxy, alkylalkoxy, alkylsulfonyl, arylsulfonyl, cyano, aryl, heteroaryl, heterocyclyl, heterocyclyl heterocyclylalkoxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, optionally substituted phenoxy; - C ::: C-Rb-; - (CH2) m- (Z) n- (CO) -Rc; - (CH2) m- (Z) n-SO2- (NRd) n-Rc; wherein m and n each independently is 0 or 1, Z is O or NRd, Rb is H, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, hydroxyalkyl, alkoxyalkyl, alkylsulfonylalkyl, aminoalkyl, cyanoalkyl, alkylsilyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl; and heterocyclylalkyl; Rc is H, alkyl, hydroxy, alkoxy, amino, hydroxyalkyl or alkoxyalkyl, and each Rd is independently H or alkyl; R6 is H, alkyl, halo, haloalkyl, amino, or alkoxy; R7 and R8 each independently is H, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, alkylsulfonyl, alkylsulfonylalkyl, aminocarbonyloxyalkyl, hydroxycarbonyl, hydroxyalkyloxycarbonylalkyl, aryl, aralkyl, arylsulfonyl, heteroaryl, heteroarylalkyl, heteroarylsulfonyl, heterocyclyl, heterocyclylalkyl; or - (C = O) -Re; wherein Re is alkyl, alkoxy, cycloalkyl, cycloalkoxy, cycloalkylalkyl, cycloalkylalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, aralkyl, aralkoxy, heteroaralkyl, heteroaralkoxy, - (CH2) p-C (= O) -Rf; - (CH = CH) -C - (= O) -Rf, or -CH (NH2) -Rg, where Rf is H, hydroxy, alkyl, alkoxy, cycloalkyl, cycloalkoxy, cycloalkylalkyl, cycloalkylalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, aralkyl, aralkoxy, heteroaralkyl, heteroaralkoxy, or amino; p is 2 or 3; Rg is H, alkyl, hydroxyalkyl, aminoalkyl, optionally substituted phenyl, benzyl, guanidinylalkyl, carboxyalkyl, amidoalkyl, thioalkyl or imidazolalkyl. |
| priorityDate | 2005-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 49.